Main Article Content


The aim of the study was to identify predictors of severe pneumonia caused by the SARS-CoV-2 virus and to describe the general characteristics of patients hospitalized in the reanimatology and intensive theraphy of the Bukhara Regional Infectious Diseases Hospital.

Results. Clinical, laboratory and instrumental data of 110 patients hospitalized in the reanimatology and intensive theraphy were studied, and predictors of severe pneumonia caused by the SARS-CoV-2 virus were identified. The contribution of a number of factors to the development of a severe course of the disease and the risk of an unfavorable outcome was determined: male gender, age over 70,5 years and concomitant diseases and severe respiratory failure.

Conclusion. Clinical characteristics of a typical patient with severe COVID-19 who is admitted to the RIT: an elderly patient with an increased body weight, an underestimated concomitant pathology at the pre-hospital stage, and severe respiratory failure.


SARS-CoV-2 COVID-19 risk factors pneumonia

Article Details

How to Cite
Husenova Z. Z, & Oblokulov A. R. (2021). CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS OF PATIENTS WITH SEVERE FORM OF COVID-19. Central Asian Journal of Medical and Natural Science, 2(3), 282-285.


  1. 1. WHO. Rolling updates on coronavirus disease (COVID19). https: //www.worldometers. info / coronavirus /. Accessed 16 Apr / 2020.
  2. 2. Ulmasova S.I., Atabekov N.S., Kasimov I.A., Shomansurova Sh.Sh. On the study of the etiological and epidemiological characteristics of the new coronavirus infection (COVID-19) in the world. // Infection, immunity and pharmacology. 1/2021 p. 79-87.
  3. 3. Yang X, Yu Y, Xu J et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8 (5): 475–81,
  4. 4. Oblokulov Abdurashid Rakhimovich, Kholov Uktam Asadovich, Niyozov Gulom Eshmuradovich, Ergashov Maqsud Muzaffarovich, Khusenova Zilola Zakhirovna. (2021). Extrapulmonal manifestations of COVID-19. Infection, immunity and pharmacology, No. 1. 62-66.
  5. 5. Niyazov G.E., Oblokulov A.R., Pondina A.I. et al. (2020) Clinical and epidemiological characteristics of COVID-19 patients // New Day in Medicine. No. 4 (32) 110-115 p.
  6. 6. Williams EJ et al. (2020) Routine measurement of serum procalcitonin allows antibiotics to be safely withheld in patients admitted to hospital with SARS-CoV-2 infection. medRxiv. doi. org / 10.1101 / 2020.06.29.20136572.
  7. 7. Abdurashid Rahimovich Oblokulov, Zilola Zohirovna Husenova, Maksudjon Muzaffarovich Ergashev. (2021). Procalcitonin as an Indicator of Antibacterial Therapy in Covid-19. Annals of the Romanian Society for Cell Biology, Volume 25: Issue 3.5220-5224.
  8. 8. Oblokulov, A.R., Niyozov, G.E. (2020). Clinical and epidemiological characteristics of patients with COVID-19. International Journal of Pharmaceutical Research, 12 (4), pp. 3749-3752.
  9. 9. Bayzhdanov A.K., Khikmatullaeva A.S., Ibadullaeva N.S. and others. Disruption of the blood coagulation system in COVID-19. // Infection, immunity and pharmacology. 1/2021 p. 7-12.
  10. 10. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. The Lancet 2020 May;395(10234):1417-8.
  11. 11. Levi M, Scully M. How I treat disseminated intravascular coagulation. Blood 2018 Feb;131(8):845-54.
  12. 12. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy.JAMA. 2020. doi: 10.1001/jama.2020.4683.
  13. 13. Anesi GL. Coronavirus disease 2019 (COVID-19): Critical care and airway management issues. Available from: https://www. coronavirus-disease-2019-covid-19-critical- care-and-airway-management-issues.
  14. 14. Maves RC, Downar J, Dichter JR, et al. Triage of scarce critical care resources in COVID-19 an implementation guide for regional allocation: an expert panel report of the task force for mass critical care and the American college of chest physicians. Chest. 2020; S0012-3692(20)30691-7. doi: 0.1016/j.chest.2020.03.063